Page last updated: 2024-09-04

cyc 202 and Cancer of Ovary

cyc 202 has been researched along with Cancer of Ovary in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Butler-Manuel, S; Chivers, P; Coley, HM; Crook, T; Giannopoulos, T; Lovell, DP; Madhuri, K; Papacharalbous, E; Safuwan, NA	1

Other Studies

1 other study(ies) available for cyc 202 and Cancer of Ovary

Article	Year
The cyclin-dependent kinase inhibitor p57(Kip2) is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancer. British journal of cancer, 2012, Jan-31, Volume: 106, Issue:3 Topics: Antineoplastic Agents; Carboplatin; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; DNA Methylation; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Humans; Ovarian Neoplasms; Purines; Roscovitine	2012

Article

Year

The cyclin-dependent kinase inhibitor p57(Kip2) is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancer.

British journal of cancer, 2012, Jan-31, Volume: 106, Issue:3

Topics: Antineoplastic Agents; Carboplatin; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; DNA Methylation; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Humans; Ovarian Neoplasms; Purines; Roscovitine

2012